Macrogenics Inc SEC Filings

MacroGenics (MGNX)Exhibit 99.1 to this Form 8-K. The information in this report, including Exhibit 99.1, is provided as “furnished” under the Exchange Act and is not deemed “filed.”

MacroGenics, Inc. reported Q3 results showing total revenue of $72.8 million versus $110.7 million a year ago, reflecting lower milestone revenue, partly offset by stronger contract manufacturing. Contract manufacturing revenue rose to $19.8 million from $4.6 million. Research and development expense declined to $32.7 million from $40.5 million.

The company generated quarterly net income of $16.8 million (basic and diluted EPS $0.27), compared with $56.3 million last year. Year to date, it recorded a net loss of $60.5 million as operating cash outflows reached $124.1 million. Cash and cash equivalents were $80.1 million with marketable securities of $66.3 million. Stockholders’ equity was $67.0 million.

In June, MacroGenics sold future ZYNYZ royalties to Sagard for $70.0 million, recognizing a liability of $70.3 million with an estimated effective interest rate of 18.6% and booked $3.3 million non-cash interest in Q3. It also recognized $50.0 million from two Sanofi regulatory milestones, included in accounts receivable at quarter end. Subsequent to quarter end, Gilead nominated a second research program and exercised its option, obligating a total of $25.0 million. Shares outstanding were 63,258,532 as of November 7, 2025. Management cites a cash runway into late 2027.

William K. Heiden, a director of MacroGenics, Inc. (MGNX), reported two open-market purchases of the company's common stock. On 08/19/2025 he purchased 50,500 shares at aggregate prices reported as $1.52 with trade prices in a range of $1.48 to $1.59, bringing his direct beneficial ownership to 61,500 shares. On 08/20/2025 he purchased an additional 49,500 shares at an aggregate price reported as $1.49 with trade prices in a range of $1.46 to $1.50, increasing his direct beneficial ownership to 111,000 shares. The Form 4 was signed by attorney-in-fact Beth A. Smith on 08/21/2025.

Thomas Spitznagel, Sr. VP Technical Ops at MacroGenics, Inc. (MGNX), acquired 30,000 shares of common stock through the exercise of employee stock options on 08/15/2025. The options had an exercise price of $1.58 and convert to 30,000 shares upon exercise. After the reported transaction, 30,000 shares are beneficially owned directly. The option grant vests 25% one year after the grant date with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

MacroGenics insider award: Senior Vice President and General Counsel Jeffrey Stuart Peters received an employee stock option grant for 30,000 shares on 08/15/2025. The option has an exercise price of $1.58, vests 25% after one year with the remaining 75% vesting in 12 substantially equal quarterly installments, and expires on 08/15/2035. Following the reported transaction Mr. Peters beneficially owns 30,000 common shares subject to the option on a direct basis. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Scott Koenig, a director of MacroGenics, Inc. (MGNX), reported vested restricted stock units (RSUs) on 08/13/2025 that converted into common stock. The Form 4 shows two separate RSU vesting transactions under code M, totaling 52,829 RSUs (21,165 and 31,664) with a reported price of $0 per unit because each RSU represents a contingent right to one share. The filing states these vestings occurred pursuant to a Separation and Consulting Agreement that caused 50% of each outstanding unvested RSU to vest, and that vested shares will be delivered as soon as practicable. The Form is signed by an attorney-in-fact on 08/15/2025. The reported beneficial ownership figures following the transactions are shown as 798,580 and 830,244 shares on the two reporting lines.

Insider option grant to CEO/Director MacroGenics reported that Eric Blasius Risser, who serves as President and CEO and a director, was granted an employee stock option covering 550,000 shares of common stock with an exercise price of $1.66. The option was granted with an exercise schedule that vests 25% one year after grant and the remaining 75% in 12 substantially equal quarterly installments thereafter. The options are exercisable through 08/13/2035 and are directly owned by the reporting person following the transaction.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,960,000 shares of MacroGenics, Inc. (MGNX), equal to 9.45% of the outstanding common stock based on 63,090,323 shares outstanding as of May 9, 2025. The filing discloses that Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), and Mr. Boyd, as managing member of Armistice Capital, each have shared voting and shared dispositive power over these shares and hold no sole voting or dispositive power. The Master Fund is the direct holder and retains the right to receive dividends or sale proceeds. This is an amendment (No. 5) to the Schedule 13G filed with the SEC.